CDC - Malaria - Travelers - Malaria Information and Prophylaxis, by Country

CDC - Malaria - Travelers - Malaria Information and Prophylaxis, by Country

Malaria Information and Prophylaxis, by Country [A]

The information presented in this table is consistent1 with the information in the Health Information for International Travel 2014 (CDC's Yellow Book).

1. A
2. B
3. C
4. D
5. E
6. F
7. G
8. H
9. I
10. J
11. K
12. L
13. M
14. N
15. O
16. P
17. Q
18. R
19. S
20. T
21. U
22. V
23. W
24. X
25. Y
26. Z

Country	Areas with Malaria	Estimated relative risk of Malaria for US Travelers2	Drug Resistance3	Malaria Species4	Recommended Chemoprophlaxis5	Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Afghanistan	April–December in all areas at altitudes below 2,500 m (8,202 ft).	High6	Chloroquine	P. vivax 80-90% P. falciparum 10-20%	Atovaquone-proguanil, doxycycline, or mefloquine	1) Month(s) of travel 2) City(ies) of travel 3) Altitude of city(ies) of travel Altitude information for Afghanistan
Albania	None	None	Not Applicable	Not Applicable	Not Applicable
Algeria	Rare indigenous cases	No information	Chloroquine	P. falciparum, P. vivax	Mosquito avoidance only.
American Samoa (U.S.)	None	None	Not Applicable	Not Applicable	Not Applicable
Andorra	None	None	Not Applicable	Not Applicable	Not Applicable
Angola	All	High	Chloroquine	P. falciparum 90% P. ovale 5% P. vivax 5%	Atovaquone-proguanil, doxycycline, or mefloquine
Anguilla (U.K.)	None	None	Not Applicable	Not Applicable	Not Applicable
Antarctica	None	None	Not Applicable	Not Applicable	Not Applicable
Antigua and Barbuda	None	None	Not Applicable	Not Applicable	Not Applicable
Argentina	None	None	Not applicable	Not applicable	Not applicable
Armenia	None	None	Not Applicable	Not Applicable	Not Applicable
Aruba	None	None	Not Applicable	Not Applicable	Not Applicable
Australia	None	None	Not Applicable	Not Applicable	Not Applicable
Austria	None	None	Not Applicable	Not Applicable	Not Applicable
Azerbaijan	May–October in rural areas below 1,500 m (4,921 ft). None in Baku.	Very Low	None	P. vivax 100%	Mosquito avoidance only	1) Month(s) of travel 2) City(ies) of travel 3) Altitude of city(ies) of travel Altitude information for Azerbaijan
Azores (Portugal)	None	None	Not Applicable	Not Applicable	Not Applicable

1. The information presented herein was accurate at the time of publication; however, factors that can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection, can markedly affect local malaria transmission patterns.
2. This estimate of risk is based on numbers of cases of malaria reported in US travelers and the estimated volume of travel to these countries. In some instances the risk may be low because the actual intensity of transmission is low in that country. In other instances, significant malaria transmission may occur only in small focal areas of the country where US travelers seldom go. Thus even though the risk for the average traveler to that country may be low, the risk for the rare traveler going to the areas with higher transmission intensity will of course be higher. For some countries that are rarely visited by US travelers, there is insufficient information to make a risk estimate.
3. Refers to P. falciparum malaria unless otherwise noted.
4. Estimates of malaria species are based on best available data from multiple sources.
5. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
6. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
7. Primaquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.